ALNA - Allena Pharmaceuticals, Inc.
6.35 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 6.60 |
| Open | 6.53 |
| Bid | 6.23 x 800 |
| Ask | 6.94 x 800 |
| Day's Range | 6.31 - 6.53 |
| 52 Week Range | 4.80 - 17.26 |
| Volume | 8,467 |
| Avg. Volume | 40,187 |
| Market Cap | 132.175M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.43 |
- Simply Wall St.•yesterday
Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52%
Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) shareholders, the stock is a lot lower today than it was a year ago. The sh...
- GlobeNewswire•yesterday
Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Allene Diaz to its Board of Directors. “We are pleased to welcome Allene to our Board of Directors,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “Allene joins our team at an opportune time, as we advance our ongoing Phase 3 URIROX™ program and make progress in our quest to deliver the first therapeutic for patients with enteric hyperoxaluria.
- GlobeNewswire•22 days ago
Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced an agreement with the Duke Clinical Research Institute (DCRI), a leading academic research institute within Duke University School of Medicine, to support the URIROX-2 Phase 3 clinical trial of reloxaliase in enteric hyperoxaluria. DCRI will establish and lead an Academic Coordinating Center (ACC) for Allena’s URIROX-2, one of two ongoing pivotal Phase 3 clinical trials evaluating the safety and efficacy of reloxaliase as a novel therapy for patients with enteric hyperoxaluria.
- GlobeNewswire•last month
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update. “We have made significant progress in our clinical development programs over the last few months, including securing alignment with the FDA on our strategy to pursue accelerated approval for reloxaliase in enteric hyperoxaluria, initiating URIROX-2, our second pivotal Phase 3 trial, and advancing enrollment in both URIROX-1, our first pivotal Phase 3 trial, and in Study 206, our Phase 2 basket study of reloxaliase in patients with primary or enteric hyperoxaluria and advanced chronic kidney disease,” said Louis Brenner, M.D., Chief Executive Officer of Allena Pharmaceuticals.
- GlobeNewswire•last month
Allena Pharmaceuticals, Inc. to Present at 39th Annual Cowen & Co. Health Care Conference
NEWTON, Mass., March 05, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing.
- GlobeNewswire•3 months ago
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Operating Officer at Allena, will be promoted to Chief Executive Officer and appointed to the Board of Directors effective February 1, 2019. Dr. Brenner will succeed Alexey Margolin, Ph.D. as Chief Executive Officer. Dr. Margolin, who co-founded Allena in 2011, will transition to Chairman of the Board effective February 1, 2019. He will continue advising the company in this new role. Louis Brenner, M.D. has served as Chief Operating Officer of Allena since April 2015 and as President since February 2017.
- GlobeNewswire•3 months ago
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
Allena’s URIROX program consists of two pivotal Phase 3 clinical trials, URIROX-1 and URIROX-2, which are designed to evaluate the safety and efficacy of reloxaliase in patients with enteric hyperoxaluria. URIROX-1 is currently enrolling patients, and Allena initiated URIROX-2 in the fourth quarter of 2018.
- Insider Monkey•4 months ago
Do Hedge Funds Love Allena Pharmaceuticals, Inc. (ALNA)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
- GlobeNewswire•5 months ago
Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the third quarter ended September 30, 2018 and also provided a business update. “As new research emerges on oxalate’s damaging effects on the kidneys, we are encouraged by the growing awareness of enteric hyperoxaluria and widespread focus on addressing the significant burden of kidney stone disease and kidney damage that it causes.
- GlobeNewswire•5 months ago
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November
NEWTON, Mass., Nov. 06, 2018 -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class,.
- Zacks•9 months ago
Allena Pharmaceuticals Enters Oversold Territory
Allena Pharmaceuticals has been on a bit of a cold streak lately but there might be light at the end of the tunnel for this overlooked stock.
- Simply Wall St.•last year
Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
The most recent earnings announcement Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...
